Clinical trials: Stage IV, NSCLC
Non-small Cell Lung Cancer
Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer
This is a prospective, single-arm, single-center, exploratory clinical trial to evaluate the efficacy and safety of the PD-1 antibody tirelizumab combined with chemotherapy monotherapy in patients with relapsed/metastatic…
- Trial name
- NCT05965102
- Testing
- Tirelizumab；Chemotherapy monotherapy
- Volunteers
- 31 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Malignant Non-small Cell Neoplasm of Lung Stage IV
A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
This research study is studying capmatinib as a treatment for advanced non-small cell lung cancer with MET exon 14 skipping, where the participant has already received prior therapy with a MET inhibitor.
- Trial name
- NCT02750215
- Testing
- Capmatinib (INC280)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Carcinoma, Non-Small-Cell Lung
CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
The primary objectives of this study are to evaluate the safety and tolerability of CS-7017 administered orally twice a day in combination with erlotinib, and to assess the pharmacokinetics of CS-7017 in combination with…
- Trial name
- NCT01199068
- Testing
- CS-7017, Erlotinib
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Stage IIIB or IV Non-Small Cell Lung Cancer
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
This Phase III clinical trial which incorporates an initial Phase II component will determine the survival of advanced Non-small cell lung cancer patients when treated with MK0683 and paclitaxel plus carboplatin
- Trial name
- NCT00473889
- Testing
- vorinostat, Comparator: paclitaxel, Comparator: carboplatin
- Volunteers
- 253 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
This open-label, single-arm study will evaluate the safety and efficacy of Tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer who have completed 4 cycles of standard platinum-based…
- Trial name
- NCT01230710
- Testing
- Erlotinib
- Where
- 7 sites in India
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Metastatic Lung Cancer
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG
Patient with histologically proven NSCLC in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. Combination with chemotherapy is possible.
- Trial name
- LIBERTYLUNG (NCT04790682)
- Testing
- assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.
- Where
- 3 sites in France
- Volunteers
- 300 people
- Sponsor
- Institut Curie
Lung Cancer
Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004159
- Testing
- gemcitabine hydrochloride, paclitaxel
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Alabama at Birmingham
Stage IV Non-small Cell Lung Cancer
Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
Current therapies for Stage IV non-small cell lung cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV lung…
- Trial name
- NCT00003497
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Burzynski Research Institute
Non-Small Cell Lung Cancer (NSCLC), Hyperlipidemia
Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC
For Patients and Families Brief Title: Management of 1L Lorlatinib with Hyperlipidemia in ALK+ Advanced NSCLC What is this study about? This study is for people with ALK-positive non-small cell lung cancer (NSCLC) who are taking…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Hyperlipidemia, ALK Gene Mutation, ALK-positive
- Trial name
- NCT07674524
- Testing
- For Part A - Observational Cohort:, Part B: Intensive Lipid-Lowering Group, For Part B - Intensive Group
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
Advanced Non-Small Cell Lung Cancer
Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine whether S-1 in combination with Cisplatin is effective as 1st line therapy in slowing tumor activity in patients with advanced non-small cell lung cancer.
- Trial name
- NCT00651833
- Testing
- S-1
- Volunteers
- 60 people
- Sponsor
- Taiho Oncology, Inc.
Non-Small Cell Lung Cancer
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
The purpose of this study is to determine if adding ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with advanced lung cancer.
- Trial name
- ATRACT-1 (NCT00662597)
- Testing
- ASA404, carboplatin, Paclitaxel
- Where
- 248 sites in United States, Argentina and 24 more
- Volunteers
- 1,285 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
This phase II trial studies how well image guided hypofractionated radiation therapy works with nelfinavir mesylate, pembrolizumab, nivolumab, and atezolizumab in treating patients with melanoma, lung cancer, or kidney cancer…
- Conditions
- Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT03050060
- Testing
- Atezolizumab, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Washington
Breast Cancer, Colorectal Cancer
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
RATIONALE: Dalteparin may be effective in inhibiting the growth of blood vessels in tumors, decreasing the risk of metastatic cancer, preventing the formation of blood clots, and improving quality of life in treating patients…
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00003674
- Testing
- dalteparin, standard therapy
- Where
- 20 sites in United States, Canada
- Volunteers
- 141 people
- Sponsor
- Alliance for Clinical Trials in Oncology
NSCLC Stage IV
Outpatient Pulmonary Rehabilitation in Non-small-cell Lung Cancer Receiving Immunotherapy
The aim of this prospective study is to evaluate the effects of an outpatient pulmonary rehabilitation program on the quality of life, performance and tumor growth of metastatic lung cancer patients receiving ongoing…
- Trial name
- OPAL (NCT06436625)
- Testing
- outpatient pulmonary rehabilitation
- Where
- Austria
- Volunteers
- 70 people
- Sponsor
- Karl Landsteiner Institute for Lung Research and Pneumological Oncology
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma, hormone receptor positive HER2 negative breast cancer that has spread from where it first started…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma
- Trial name
- NCT05098210
- Testing
- Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Fred Hutchinson Cancer Center
Lung Cancer
Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy
RATIONALE: Vaccines made from a person's tumor cells may help the body build an effective immune response to kill non-small cell lung cancer cells.
- Trial name
- NCT00503568
- Testing
- Ad100-gp96Ig-HLA A1
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Miami
Non-small Cell Lung Cancer
Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)
BMS-275183 given orally twice weekly to patients pretreated for locally advanced or metastatic NSCLC will show anti-tumor activity in any of the 3 separate cohorts of the patients enrolled: Cohort I: Patients previously treated…
- Trial name
- NCT00359450
- Testing
- BMS-275183 (oral taxane)
- Where
- 30 sites in United States, Belgium and 6 more
- Volunteers
- 186 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer
Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
The primary objective of this study is to determine the overall response rate (complete response + partial response) to a combination of bavituximab plus carboplatin and paclitaxel in patients with previously untreated locally…
- Trial name
- NCT00687817
- Testing
- bavituximab plus paclitaxel and carboplatin
- Where
- 9 sites in India
- Volunteers
- 49 people
- Sponsor
- Peregrine Pharmaceuticals
Non-Small-Cell Lung Carcinoma
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
This is a Phase IIb/III randomized, double-blind, placebo-controlled study to compare the efficacy and safety of first-line therapy combined with TG4010 or placebo in stage IV non-small cell lung cancer (NSCLC).
- Trial name
- TIME (NCT01383148)
- Testing
- TG4010
- Where
- 72 sites in United States, Belgium and 8 more
- Volunteers
- 222 people
- Sponsor
- Transgene
NSCLC Stage IV
HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC
This is a Phase 1, open-label, multicenter, dose escalation study of HY1272 (administered via IV) evaluating both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) in patients diagnosed with locally advanced or…
- Trial name
- NCT06218940
- Testing
- HY1272
- Volunteers
- 40 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.